On December 4, 2019 Nordic Nanovector ASA (OSE: NANO) reported that new data from preclinical studies investigating the effect of Betalutin (177Lu-lilotomab satetraxetan) on non-Hodgkin’s lymphoma (NHL) cell lines will be presented in a poster at the 61st American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting & Exposition (7-10 December 2019 in Orlando, FL, USA) (Press release, Nordic Nanovector, DEC 4, 2019, View Source [SID1234551945]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The ongoing research programme aims to investigate resistance mechanisms that enable NHL cells to survive Betalutin treatment and to identify molecules that, when used in combination with Betalutin, could overcome that resistance. The findings of this research could direct future programmes designed to expand the use of Betalutin-based therapies in NHL patients.

The research being presented at ASH (Free ASH Whitepaper) builds on data previously presented (at the European Haematology Association annual meeting in June 2018) describing how a screen of more than 50 different NHL cell lines identified some cell lines that were resistant to Betalutin. Two resistant cell lines were aggressive diffuse large B-cell lymphoma (DLBCL) cell lines (the double-hit/double-expressor ABC-DLBCL cell lines RIVA and U2932).

The new poster reports how these two aggressive DLBCL cell lines have been used in a new screen where Betalutin has been combined with 384 different anti-cancer drugs to identify the Betalutin/drug combinations that could potentially contribute to reverting resistance.

Jostein Dahle, Chief Scientific Officer of Nordic Nanovector, said: "Our ongoing research programmes and collaborations continue to help us understand how NHL cells react to Betalutin treatment. Understanding the mechanisms of resistance to Betalutin, and how to overcome them, is crucial for being able to deliver optimal treatment to patients with difficult to treat tumours. In the case of Betalutin-based treatment, which to date has demonstrated an encouraging clinical profile, such combination strategies could further enhance its potential to become an important option for NHL patients."

Abstract 2574

Abstract title: The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37 Targeted Radioimmunotherapy in Activated B Cell like Diffuse Large B Cell Lymphoma Cell Lines

Authors: G.E. Rødland et al.

Session Name: 605. Molecular Pharmacology, Drug Resistance-Lymphoid and Other Diseases: Poster II

Date: Sunday, 8 December 2019
Presentation Time: 6:00 PM – 8:00 PM Eastern time
Location: Orange County Convention Center, Hall B

The abstract is available at View Source and the poster will be published on the Nordic Nanovector website to coincide with the session.

About ASH (Free ASH Whitepaper)

The ASH (Free ASH Whitepaper) annual meeting is the premier event for scientific exchange in the field of haematology, attracting more than 20,000 attendees from all over the world. Typically, more than 5,000 scientific abstracts are submitted each year, and more than 3,000 abstracts are accepted for oral and poster presentations through an extensive peer review process. View Source